Form D · Biotechnology
Avalyn Pharma Inc.
Seattle, WA · CIK 0001540171
Offering snapshot reported Oct 10, 2023 · SEC filing
- Reported sold
- $189M Offering amount: $189M
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 22, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 10, 2023 | Initial | $189,182,622 | No comparison | 26 | SEC filing |
| May 8, 2020 | Initial | $35,499,998 | No comparison | 8 | SEC filing |
| May 24, 2017 | Amendment | $18,207,187 | $1,585,714vs Mar 24, 2017 | 46 | SEC filing |
| Mar 24, 2017 | Initial | $16,621,473 | No comparison | 45 | SEC filing |
| Aug 12, 2015 | Amendment | $2,179,480 | $1,089,480vs Nov 16, 2012 | 41 | SEC filing |
| Mar 24, 2015 | Amendment | $1,654,480 | $564,480vs Nov 16, 2012 | 34 | SEC filing |
| Nov 16, 2012 | Initial | $1,090,000 | No comparison | 22 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-494182
Source: Form D, filed Oct 10, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Tiba Aynechi | Director |
| Lyn Baranowski | Director, Executive |
| Daniel D. Burgess | Director |
| Jill Carroll | Director |
| Sofia Ioannidou | Director |
| Michael J. Kamdar | Director |
| Jonathan Leff | Director |
| Jonathan Leff, M.D. | Director |
| Cassandra Gianna Luca | Director |
| Robert Mittendorff | Director |
| Peter Moldt | Director |
| A. Bruce Montgomery | Director, Executive |
| Bruce Montgomery, M.D. | Director, Executive |
| Niall O'donnell | Director |
| Ketan Patel | Director |
| Heather Preston | Director |
| Naveed Siddiqi | Director |
| Mark W. Surber, Ph.D. | Executive |
| Richard G. Vincent | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
701 Pike Street Suite 1500
Seattle, WA, 98101
Seattle, WA, 98101